Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Affiliations

¹ Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada.
² Vattikuti Urology Institute and VUI Center for Outcomes Research Analytics and Evaluation, Henry Ford Hospital, Detroit, MI, USA. Electronic address: firas.abdollah@gmail.com.

Comment

Maxine Sun et al. Eur Urol. 2015 Jul.

. 2015 Jul;68(1):162-3.

doi: 10.1016/j.eururo.2015.03.054.

¹ Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada.
² Vattikuti Urology Institute and VUI Center for Outcomes Research Analytics and Evaluation, Henry Ford Hospital, Detroit, MI, USA. Electronic address: firas.abdollah@gmail.com.

No abstract available

Comment on

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Antonarakis ES, et al. N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3. N Engl J Med. 2014. PMID: 25184630 Free PMC article.